Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-104 in Open-Angle Glaucoma or Ocular Hypertension
NCT00656240Phase 2
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- Santen Pharmaceutical
- Modality
- Small Molecules
- Drugs
- DE-104
- Conditions
- open-angle glaucoma (OAG)ocular hypertension
01
Overview
Phase 2, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing DE-104 with Vehicle (2 arms). Primary endpoint: Intraocular Pressure. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
DE-104
DE-104 ophthalmic solution
Vehicle
DE-104 vehicle (Placebo)
03
Who it enrols
Patients diagnosed with primary open-angle glaucoma or ocular hypertension, aged 20-74. Females of childbearing potential must use reliable contraception and have a negative pregnancy test.
04
Endpoints
Primary
Intraocular Pressure
Secondary
Safety and Adverse Events
Beyond the preview
Go deeper on NCT00656240.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656240.